Application of the Scleroderma Clinical Trials Consortium Damage Index in patients with juvenile systemic sclerosis

Application of the Scleroderma Clinical Trials Consortium Damage Index in patients with juvenile systemic sclerosis

Abstract Background Juvenile systemic sclerosis (jSSc) can lead to permanent and irreversible anatomical or physiological dysfunction. The Scleroderma Clinical Trials Consortium-Damage Index (SCTC-DI), which has been employed and validated in adult patients, can quantify organ damage and predict mor...

Full description

Saved in:
Bibliographic Details
Main Authors: Caihui Zhang, Changyan Wang, Sihao Gao, Mingsheng Ma, Wei Wang, Tianyu Zhang, Yu Zhang, Xiaoyan Tang, Zhuo Li, Zhixing Sun, Lin Wang, Hongzhong Jin, Xiaofeng Zeng, Hongmei Song
Format: Article
Language:English
Published: BMC 2025-05-01
Series:Pediatric Rheumatology Online Journal
Subjects:
Systemic sclerosis
Children
Disease severity
Organ damage burden
Online Access:https://doi.org/10.1186/s12969-025-01110-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12969-025-01110-6

Similar Items